Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07523542 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus

Name: SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus — clinical trial record (NCT07523542)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: SELECT-SLE

StatusRecruiting

PhasePhase 1/2

SponsorBeijing Biotech

Started2026-03-02

View on ClinicalTrials.gov ↗

Beijing Biotech

32 trials monitored

See all monitored trials

Lupus (SLE)

648 trials monitored

See 25 trials at risk

study evaluates a biomarker-guided strategy to assign adults with refractory SLE to autologous CAR-T therapy targeting either CD19 or BCMA. Participants undergo centralized screening immunophenotyping to determine whether their disease appears B-cell-dominant (CD19-preferred) or plasma-cell-dominant (BCMA-preferred), followed by leukapheresis, lymphodepletion, and a single CAR-T infusion. The main goals are to assess safety, determine a recommended Phase 2 dose within each arm, and estimate remission rates by Week 24.

Trial Details

NCT Number	NCT07523542
Lead Sponsor	Beijing Biotech
Conditions	REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS, Lupus Nephritis
Enrollment	24 participants
Start Date	2026-03-02
Primary Completion	2027-03-14 (estimated)
Study Completion	2028-10-17 (estimated)
Updated on ClinicalTrials.gov	2026-04-13